Merck & Co. (MRK)
(Delayed Data from NYSE)
$131.19 USD
+0.31 (0.24%)
Updated May 17, 2024 04:00 PM ET
After-Market: $131.20 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRK 131.19 +0.31(0.24%)
Will MRK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRK
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
5 Stocks Powering the Dow ETF Year to Date
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
Other News for MRK
Novo Nordisk, J&J lead R&D rankings in big pharma: report
10 Health Care Stocks Whale Activity In Today's Session
GLOBAL BROKER RATINGS: RBC cuts Inditex, Deutsche raises Roche
Dow at 40K: Leaders and laggards over the last 10,000 points
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches